Meeting
2012 ASCO Annual Meeting
10-year update of E2197: Phase III doxorubucin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.
Authors
Joseph A. Sparano
Albert Einstein College of Medicine, Bronx, NY
Joseph A. Sparano , Anne O'Neill , Robert James Gray , Edith A. Perez , Lawrence N. Shulman , Silvana Martino , Sunil S. Badve , Frederick L. Baehner , Barrett H Childs , Carl N. Yoshizawa , Steve Rowley , Nancy E. Davidson , Steven Shak , Lori J. Goldstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT00003519
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1021)
DOI
10.1200/jco.2012.30.15_suppl.1021
Abstract #
1021
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy.
First Author: Joyce O'Shaughnessy
Poster
2023 ASCO Breakthrough
Risk factors and predictors of tumor recurrence among breast cancer patients in a tertiary government hospital in the Philippines.
First Author: Omar Paningbatan Maaño
Poster
2021 ASCO Annual Meeting
Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.
First Author: Douglas W. Blayney
Poster
2018 ASCO Annual Meeting
Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).
First Author: Wolfgang Janni